Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND/AIMS: The Age-Related Eye Disease Study (AREDS) reported the beneficial impact of antioxidant and zinc supplements on the risk of progression to advanced stages of age-related macular degeneration (AMD). We evaluated the role of genetic variants in modifying the relationship between supplementation and progression to advanced AMD. METHODS: Among 4124 eyes (2317 subjects with a genetic specimen), 882 progressed from no AMD, early or intermediate AMD to overall advanced disease, including geographic atrophy (GA) and neovascular disease (NV) over the course of the clinical trial. Survival analysis using individual eyes as the unit of analysis was used to assess the effect of supplementation on AMD outcomes, with adjustment for demographic, environmental, ocular and genetic covariates. Interaction effects between supplement groups and individual complement factor H (CFH) Y402H and age-related maculopathy susceptibility 2 (ARMS2) genotypes, and composite genetic risk groups combining the number of risk alleles for both loci, were evaluated for their association with progression. RESULTS: Among antioxidant and zinc supplement users compared with the placebo group, subjects with a non-risk genotype for CFH (TT) had a lower risk of progression to advanced AMD (HR: 0.55, 95% CI 0.32 to 0.95, p=0.033). No significant treatment effect was apparent among subjects who were homozygous for the CFH risk allele (CC). A protective effect was observed among high-risk ARMS2 (TT) carriers (HR: 0.52, 95% CI 0.33 to 0.82, p=0.005). Similar results were seen for the NV subtype but not GA. CONCLUSIONS: The effectiveness of antioxidant and zinc supplementation appears to differ by genotype. Further study is needed to determine the biological basis for this interaction. TRIAL REGISTRATION NUMBER: NCT00594672, pre-results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.11.1484 · Cited by 739
Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M. J., & Seddon, J. M. (2006) · Nature Genetics · doi:10.1038/ng1873 · Cited by 599
Self-citationAssociation of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330
Self-citationA rare penetrant mutation in CFH confers high risk of age-related macular degeneration
Raychaudhuri, S., Iartchouk, O., Chin, K., Tan, P. L., Tai, A. K., Ripke, S., Gowrisankar, S., Vemuri, S., Montgomery, K., Yu, Y., et al. (2011) · Nature Genetics · doi:10.1038/ng.976 · Cited by 323
Self-citationSeddon, J. M., Reynolds, R., Maller, J., Fagerness, J. A., Daly, M. J., & Rosner, B. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3064 · Cited by 285
Self-citationYu, Y., Bhangale, T. R., Fagerness, J., Ripke, S., Thorleifsson, G., Tan, P. L., Souied, E. H., Richardson, A. J., Merriam, J. E., Buitendijk, G. H. S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr270 · Cited by 254
Self-citationSeddon, J. M., Reynolds, R., Yu, Y., Daly, M. J., & Rosner, B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.04.029 · Cited by 198
Self-citationKlein, M. L., Francis, P. J., Rosner, B., Reynolds, R., Hamon, S. C., Schultz, D. W., Ott, J., & Seddon, J. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.01.036 · Cited by 172
Self-citationChew, E. Y., Klein, M. L., Clemons, T. E., Agrón, E., & Abecasis, G. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.10.012 · Cited by 61
Cited by
Risk factors for progression of age‐related macular degeneration
Heesterbeek, T. J., Lorés‐Motta, L., Hoyng, C. B., Lechanteur, Y. T. E., & den Hollander, A. I. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12675 · Cited by 392
Towards the application of precision medicine in Age-Related Macular Degeneration
Cascella, R., Strafella, C., Caputo, V., Errichiello, V., Zampatti, S., Milano, F., Potenza, S., Mauriello, S., Novelli, G., Ricci, F., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.004 · Cited by 76
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Maurya, M., Bora, K., Blomfield, A. K., Pavlovich, M. C., Huang, S., Liu, C.-H., & Chen, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.369098 · Cited by 63
“…in neovascular AMD patients, AREDS supplements resulted in a lower risk of AMD progression to an advanced stage in high-risk ARMS2 (TT) and non-risk CFH allele (TT) group, but not in CFH high-risk allele (CC) group, yet similar results were not seen in GA (Seddon et al., 2016; Vavvas et al., 2018).”
Assel, M. J., Li, F., Wang, Y., Allen, A. S., Baggerly, K. A., & Vickers, A. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.09.008 · Cited by 48
Metadata
- Authors
- Seddon, J. M., Silver, R. E., & Rosner, B.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2016-07-28
- Volume
- 100
- Issue
- 12
- Pages
- 1731-1737
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2492485330
- Cited by
- 55
- References
- 10
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. https://app.cochat.ai/papers/10.1136/bjophthalmol-2016-308624
- The paper
- Seddon, J. M., Silver, R. E., & Rosner, B. (2016). Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2016-308624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.